Cancer Research UK enters new oncology partnership
Cancer Research UK (CRUK) and its commercial arm, Cancer Research Technology (CRT), haven entered into an agreement with TYG Oncology to develop a new vaccine for advanced cancers.
The partnership plans to take TYG’s antigen-specific, active checkpoint control cancer vaccine TYG100 and use it as a base to develop the new preventative treatment. TYG100 prevents tumour growth by targeting the hormones responsible and triggers production of antibodies. The companies have agreed to share development costs of the drug.
The drug will then be taken into Phase I testing to determine its safety and efficacy in treating sufferers of advanced solid tumours. The trial will be managed by CRUK’s Centre for Drug Development (CDD) and will be carried out over the CRUK’s nationwide Experimental Cancer Medicine Centres network. Following the trial, TYG will be given the option to retain the rights to the new product or hand them to CRUK who will continue development.
Fred Jacobs, president of TYG oncology, said: “We are very pleased to be working in partnership with the clinical experience and expertise from Cancer Research UK to advance TYG100. Cancer Research UK’s sponsorship of the Phase I clinical trial is a significant technical and financial validation of our novel therapeutic vaccine. TYG100 will be attacking some of the most difficult and deadliest solid tumours, including pancreatic and gastro-oesophageal cancers.”
Dr Nigel Blackburn, Cancer Research UK’s director of drug development, said: “We hope that next generation cancer vaccines like this one will build on the widespread success of existing hormonal treatments – such as those targeting oestrogen in breast cancer and testosterone in prostate cancer. It’s a very promising area of research and we’re excited to be working with TYG oncology to take this to the next stage.”
“Our Clinical Development Partnerships are a novel approach that allows companies to benefit from Cancer Research UK’s extensive drug development resources in a way that is mutually beneficial and that ultimately helps new treatments reach patients more quickly.”
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT …
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …